We narrowed to 8,795 results for: PAN

#138327-AAV9

Ready-to-use AAV9 particles produced from pAAV-synapsin-HaloCaMP1a-EGFP (#138327). In addition to the viral particles, you will also receive purified pAAV-synapsin-HaloCaMP1a-EGFP plasmid DNA. Synapsin-driven HaloCaMP1a, a far-red calcium sensor, fused to EGFP. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Deo et al Nat Chem Biol. 2021 Jun;17(6):718-723. d

Sept. 15, 2021

Academic Institutions and Nonprofits only

#138328-AAV9

Ready-to-use AAV9 particles produced from pAAV-synapsin-HaloCaMP1b-EGFP (#138328). In addition to the viral particles, you will also receive purified pAAV-synapsin-HaloCaMP1b-EGFP plasmid DNA. Synapsin-driven HaloCaMP1b, a far-red calcium sensor, fused to EGFP. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Deo et al Nat Chem Biol. 2021 Jun;17(6):718-723. d

Sept. 15, 2021

Academic Institutions and Nonprofits only

#69571-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-C-CreintG (#69571). In addition to the viral particles, you will also receive purified pAAV-EF1a-C-CreintG plasmid DNA. EF1a-driven expression of optimized C-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-N-CretrcintG (Addgene catalog# 69570) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#69570-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-N-CretrcintG (#69570). In addition to the viral particles, you will also receive purified pAAV-EF1a-N-CretrcintG plasmid DNA. EF1a-driven expression of optimized N-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-C-CreintG (Addgene catalog# 69571) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#179463-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-JEDI-2P-Kv-WPRE (#179463). In addition to the viral particles, you will also receive purified pAAV-hSyn-JEDI-2P-Kv-WPRE plasmid DNA. hSyn-driven expression (soma and AIS-localized) of the genetically encoded voltage indicator JEDI-2P. These AAV preparations are suitable purity for injection into animals.

Francois St-Pierre

Liu et al Cell. 2022 Aug 16. pii: S0092-8674(22)00

Jan. 24, 2024

Academic Institutions and Nonprofits only

#179464-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-JEDI-2P-WPRE (#179464). In addition to the viral particles, you will also receive purified pAAV-hSyn-JEDI-2P-WPRE plasmid DNA. hSyn-driven expression of the genetically encoded voltage indicator JEDI-2P. These AAV preparations are suitable purity for injection into animals.

Francois St-Pierre

Liu et al Cell. 2022 Aug 16. pii: S0092-8674(22)00

Jan. 24, 2024

Academic Institutions and Nonprofits only

#139505-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO-PPO-Venus (#139505). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-PPO-Venus plasmid DNA. EF1a-driven, Cre-dependent expression of Venus-tagged parapinopsin for spatiotemporal control of inhibitory GPCR signaling cascades. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

Oct. 28, 2021

Academic Institutions and Nonprofits only

#119036-AAV1

Ready-to-use AAV1 particles produced from pAAV-hsyn-flex-Voltron-ST (#119036). In addition to the viral particles, you will also receive purified pAAV-hsyn-flex-Voltron-ST plasmid DNA. Synapsin-driven, cre-dependent expression of genetically encoded fluorescent voltage indicator Voltron1 with a soma-targeting sequence. These AAV preparations are suitable purity for injection into animals.

Eric Schreiter

Abdelfattah et al Science. 2019 Aug 1. pii: science.aav641

April 10, 2019

Academic Institutions and Nonprofits only

#139505-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-DIO-PPO-Venus (#139505). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-PPO-Venus plasmid DNA. EF1a-driven, Cre-dependent expression of Venus-tagged parapinopsin for spatiotemporal control of inhibitory GPCR signaling cascades. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

Sept. 27, 2023

Academic Institutions and Nonprofits only

#139504-AAV5

Ready-to-use AAV5 particles produced from pAAV-CAG-DIO-PPO-Venus (#139504). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-PPO-Venus plasmid DNA. CAG-driven, Cre-dependent expression of Venus-tagged parapinopsin. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

April 10, 2024

Academic Institutions and Nonprofits only

#139504-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-DIO-PPO-Venus (#139504). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-PPO-Venus plasmid DNA. CAG-driven, Cre-dependent expression of Venus-tagged parapinopsin. These AAV preparations are suitable purity for injection into animals.

Michael Bruchas

Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

Nov. 13, 2025

Academic Institutions and Nonprofits only